clinical trial · NCT04417530
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Uveal MelanomaOcular MelanomaChoroidal MelanomaAU-011Suprachoroidal MicroinjectorPDT Laser
brief summary
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
started
Aug 5, 2020
primary completion
Apr 22, 2024
completion
Apr 22, 2024
last updated
Mar 3, 2025
detailed description
This is an open-label, ascending single and repeat dose escalation trial designed to evaluate the safety, tolerability, and preliminary efficacy of up to 4 dose levels and repeat dose regimens of belzupacap sarotalocan via suprachoroidal administration with 1 or 2 laser applications per treatment.
official title
A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol